Sunshine Biopharma Inc. is a Colorado corporation headquartered in the greater Montreal area (Canada).
Adva-27a Anticancer Drug
Sunshine Biopharma’s lead oncology compound is called Adva-27a. A small molecule, Adva-27a has been shown to be exceptionally effective at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). These and other preclinical results have been published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012. The Company is planning to conduct Adva-27a Phase I Clinical Trials for Pancreatic Cancer indication at McGill University’s Jewish General Hospital in Montreal (Canada).
On May 22nd, 2020, Sunshine Biopharma filed a patent application covering protease inhibitors for Coronavirus. In collaboration with the University of Arizona, the Company is currently developing these compounds as a treatment for COVID-19. It is anticipated that such treatment will be in the form of a tablet that can be taken at home.
Anticancer K1.1 mRNA
K1.1 is an mRNA that encodes an inhibitor of a transcription factor essential for initiation of cell division. We have recently shown that K1.1 mRNA is capable of destroying cancer cells in vitro including breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2)
Directors & Officers
Dr. Steve Slilaty
Chairman & CEO
Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona. He is currently President & CEO of Sunshine Biopharma and has an appointment as Adjunct Professor at Universite du Quebec. Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks. His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 220.127.116.11) and the development of key technology for the Human Genome Project (TrueBlue Cloning System). With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached a $1 billion market cap. At Sunshine Biopharma Dr. Slilaty is working with the same determination as he pioneers a path towards the discovery of groundbreaking drugs for the treatment of aggressive forms of cancer.
Mr. Camille Sebaaly
Mr. Sebaaly has over 20 years of experience in the engineering, development and commercialization of emerging technologies worldwide. Mr. Sebaaly was appointed as our Chief Financial Officer, Secretary and Director of Sunshine Biopharma on October 15, 2009. Previously, he held a number of senior executive positions in various areas including, financial management, business development, project management and finance. As an executive and an entrepreneur, he combines expertise in strategic planning and finance with strong skills in business development and deal structure and negotiations. In addition, Mr. Sebaaly worked in operations, general management, investor relations, marketing and business development with an emphasis on international business and marketing of advanced technologies including hydrogen generation and energy saving. Mr. Sebaaly graduated from the State University of New York at Buffalo with an Electrical and Computer Engineering Degree in 1987.
Dr. Abderrazzak Merzouki
Director & COO
Dr. Merzouki is an accomplished scientist with over 20 years of experience in virology and immunology. Dr. Merzouki obtained his Ph.D. in Virology and Immunology from Institut Armand-Frappier in Quebec and received his post-doctoral training at the University of British Columbia and the BC Center for Excellence in HIV/AIDS research. He was appointed as a Director and Chief Operating Officer of Sunshine Biopharma in February 2015. Dr. Merzouki has over 30 publications and 70 communications in various, highly respected scientific journals in the field of cellular and molecular biology. Prior to joining Sunshine, Dr. Merzouki worked at the Institute of Biomedical Engineering in the Department of Chemical Engineering at Ecole Polytechnique de Montreal, where he taught and acted as a senior scientist involved in the research and development of plasmid and siRNA-based therapies. He also worked in the area of gene therapy where he performed several preclinical studies for pharmaceutical companies involving the use of adenoviral vectors for cancer therapy and plasmid vectors for the treatment of peripheral arterial occlusions. Dr. Merzouki also has extensive expertise in the design of expression vectors, and the production and purification of recombinant proteins. He developed technologies for the production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. In addition to his academic expertise, Dr. Merzouki has a strong worldwide network of business and financial relationships.
Mr. David Natan
David Natan has served as a director of the Company since February 10, 2022. Since 2007, Mr. Natan has served as President and Chief Executive Officer of Natan & Associates, LLC, Parkland, Florida, a privately-held consulting firm offering chief financial officer services to public and private companies in a variety of industries. In addition, since April 2020 Mr. Natan has served as Executive Vice President and Chief Financial Officer for Airborne Motorworks, Inc., Spokane, WA, a privately-held aerospace transportation company, Since February 2021, Mr. Natan has also been a director and Chairperson of the Audit Committee of Global Diversified Marketing Group, Inc. (OTCMKTS: GDMK), a manufacturer, marketer and distributor of food and snack products. From February 2010 to May 2020, Mr. Natan served as Chief Executive Officer of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on the solar industry and LED lighting products. He was also Chairman of the Board of this company from April 2015 to May 2020. Additionally, Mr. Natan served in various roles of increasing responsibility with Deloitte & Touche LLP, a global consulting firm, as well as a member of the Board of Directors of various companies. Mr. Natan holds a B.A. in Economics from Boston University. Mr. Natan’s experience as a business executive and as a director of public companies qualify him to serve on our board of directors.
Dr. Andrew M. Keller
Dr. Andrew M. Keller has served as a director of the Company since February 10, 2022. From 2016 through November 2019, Dr. Keller was the Chief Medical Officer at the Western Connecticut Medical Group, Bethel CT, a multispecialty organization. He was employed by this group beginning in 1989, and in 2003 became Chief – Section of Cardiovascular Diseases. In 2014 he was appointed Chief Medical Informatics Officer. Previously, Dr. Keller was an Assistant Professor of Medicine/Radiology at Columbia University, The College of Physicians and Surgeons, NY, NY. Dr. Keller retired as a practicing physician in 2019 and in 2020, became a full time student at Quinnipiac University College of Law, where he is currently in his second year. Dr. Keller received a Doctor of Medicine degree in 1979 from The Ohio State University and a Bachelor of Arts degree in Physics, Magna Cum Laude from Ithaca College in 1975. Dr. Keller’s medical and scientific knowledge and experience qualify him to serve on our board of directors.
Dr. Rabi Kiderchah
Dr, Rabi Kiderchah is a licensed physician in Canada. From 2000 until August 2021, he was working at Argenteuil Hospital, Lachute, Quebec, Canada, as an emergency room physician. He has also worked as what is referred to in Canada as a “medecins depanneurs”, working in rural areas where there are not enough ER doctors. Since August 2011 he has worked at Rabi Kiderchah Medecin Inc. as a freelance physician in the Quebec, Canada area.
B F Borgers CPA PC
5400 West Cedar Avenue
Lakewood, Colorado 80226
Andrew I. Telsey, P.C.
12835 E. Arapahoe Road, Suite I-803
Centennial, Colorado 80112
The Directors of Sunshine Biopharma are committed to completely transparent Corporate Governance. In collaboration with our Auditors and Legal counsels, we have adopted specific guidelines to promote the interest of our shareholders and govern the corporation with the highest standards of integrity.
Sunshine Biopharma Inc.
6500 Trans-Canada Highway, 4th Floor
Pointe-Claire, Quebec H9R 0A5